Compare Enveric Biosciences Inc (ENVB) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vale SA — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Vale SA trades at $13.5 (market cap $58.70B). The key difference: Vale SA is far larger — about 8774.3× Enveric Biosciences Inc's market cap, and Vale SA pays a 8.75% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vale SA for 109 Days on average.
| ENVB | VALE | |
|---|---|---|
Market Cap | $6.69M | $58.70B |
Volume | 41,141 | 45,073,516 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $17.82 |
52-Week Low | $1.27 | $10.75 |
Typical Hold Time | 14 Days | 109 Days |
Enterprise Value | -$1.60M | $74.94B |
Dividend Yield | — | 8.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
VALE trades at $13.42, down 4.69% today amid broader sector weakness. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but net income fell to $2.35B in 2025 from $18.8B in 2022. The company maintains strong cash flow generation ($8.8B operating cash flow) and recently declared a $0.40 dividend payable September 2026.
VALE faces headwinds from iron ore price volatility and rising costs, but base metals growth provides diversification. Analyst consensus is mixed with 32% buy ratings and a $16.21 price target suggesting 21% upside. Key risks include Brazilian regulatory exposure and cyclical commodity dependence. The current valuation (P/E 27.22) appears stretched given earnings compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
